Schedule 13D ownership disclosure
Vir Biotechnology Inc
Common Stock, $0.0001 par value · CUSIP: 92764N102
Event date: 2026-11-04
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ARCH Venture Fund IX, L.P.Reported CIK 0001666306
Shares: 11,897,988 · Class: 6.9%
- ARCH Venture Fund IX Overage, L.P.Reported CIK 0001666307
Shares: 11,897,988 · Class: 6.9%
- ARCH Venture Partners IX, L.P.Reported CIK 0001723173
Shares: 11,897,988 · Class: 6.9%
- ARCH Venture Partners IX Overage, L.P.Reported CIK 0001723172
Shares: 11,897,988 · Class: 6.9%
- ARCH Venture Partners IX, LLCReported CIK 0001723174
Shares: 11,897,988 · Class: 6.9%
- Robert NelsenReported CIK 0001219042
Shares: 12,508,029 · Class: 7.3%
- Keith CrandellReported CIK 0001219039
Shares: 12,170,952 · Class: 7.1%
- Clinton BybeeReported CIK 0001219043
Shares: 11,989,718 · Class: 7.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001012975-26-001020
- Form type
- SCHEDULE 13D/A
- Filer
- Vir Biotechnology, Inc.
- CIK
- CIK 1706431
- Filed
- Nov 06, 2026
- Reporting period
- Nov 04, 2026
- Description
- Schedule 13D beneficial ownership